BioCatalystWatch
ANVSWorkspace / ANVS / OverviewCompany library
Price
Market cap
Next catalystDec 31, 2026Buntanetap — DUET-AD · Dosing completionSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Buntanetap

APP mRNA IRE × APP × Amyloid-β × Tau × α-Synuclein × TDP-43

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Buntanetap

APP mRNA IRE × APP × Amyloid-β × Tau × α-Synuclein × TDP-43

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

Buntanetap

APP mRNA IRE × APP × Amyloid-β × Tau × α-Synuclein × TDP-43

PreINDP1P2P3FilingApproved
Upcoming / outlook

Buntanetap

APP mRNA IRE × APP × Amyloid-β × Tau × α-Synuclein × TDP-43

Upcoming / outlook

Buntanetap

APP mRNA IRE × APP × Amyloid-β × Tau × α-Synuclein × TDP-43

PreINDP1P2FilingApproved
Upcoming / outlook

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ANVS PR & News

PR & News

ANVS SEC archive